An observational study in Chronic Thromboembolic Pulmonary Hypertension, sponsored by Irina E. Chazova. Recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.
Sponsored by Irina E. Chazova · Observational
The goal of this observational study is to gather information on background, medical history, symptoms and physical condition, treatment options of people with chronic thromboembolic pulmonary hypertension in real clinical practice in Russia.
The main question it aims to answer is:
Which factors most influence the prognosis of participants?
Data from international CTEPH registries indicate variable utilization rates of available treatment options. Considering the presence of national specificities in the management of CTEPH patients, coupled with the relatively low prevalence of the disease, which poses challenges for data accumulation and research, new registry POLET (Registry of Patients with chrOnic thombomboLic pumonary hypErTension) is established to investigate CTEPH patients in real-world clinical practice.
Registry Aim:
To investigate the prognosis of patients with chronic thromboembolic pulmonary hypertension based on demographic, anamnestic, clinical characteristics, and treatment regimens.
Registry Objectives:
To describe the key demographic, anamnestic, and clinical characteristics of CTEPH patients in Russia.
To identify factors influencing the frequency of hospitalizations due to clinical deterioration in CTEPH patients.
To determine the impact of anamnestic data and treatment regimens on patient prognosis (time to clinical deterioration/death).
To determine the impact of demographic and clinical characteristics on patient survival and prognosis (time to clinical deterioration/death).
Currently, preliminary retrospective data have been collected on 300 CTEPH patients, each with 1 to 15 hospitalizations at the National Medical Research Center of Cardiology named after Academician E.I. Chazov of the Ministry of Health of Russia from 2012-2024, and who are eligible for inclusion in the registry. 200 patients will be enrolled prospectively.
The following data to be extracted from electronic medical records:
Medical History Data; Clinical Characteristics and Results of Investigations and Treatments During Each Patient Hospitalization; Operability Assessment Results; PAH-Specific Therapy, Anticoagulant Therapy, Supportive Therapy: Therapy Adjustment, Doses, Presence of Side Effects; Details of Pulmonary endarterectomy; Details of BPA performed; Patient outcomes including survival. Statistical data processing will be performed using RStudio and the R programming language. Missing data will be handled with imputation approach.
This is the only study on the registry with Irina E. Chazova as lead sponsor.
Counted across the registry records on this site, refreshed daily.
operable CTEPH, non-operable CTEPH
Exclusion Criteria:
A surgical procedure to remove chronic blood clots from the pulmonary arteries
Also known as: PEA, PTE, Pulmonary thromboendarterectomy
A minimally invasive procedure used to treat chronic thromboembolic pulmonary hypertension by dilatating narrowed pulmonary arteries and improving blood flow to the lungs
Also known as: BPA
Medical treatment with any PH-specific drugs
Also known as: PH-specific therapy, PH-Targeted Medical Therapy
All-cause mortality
Time frame: Up to 5 years
All-cause mortality
Time frame: Up to 10 years
Change in distance in 6-minute walk test
Time frame: 1 year
Change in mPAP
mPAP assesed during right heart catheterization
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.